首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1576917

神經調節設備的全球市場:洞察，競爭情形，市場預測:2030年

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年10月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

2023年神經調節劑的市場規模為57.1億美元。預計到 2030 年，該市場將達到 95.6 億美元，2024 年至 2030 年的預測期間複合年增長率為 8.95%。神經調節設備的需求主要是由神經系統疾病盛行率的上升和患有慢性疼痛的患者數量的增加所推動的。此外，主要公司之間的研發和聯盟的增加也為市場成長做出了重大貢獻。社會老化進一步增加了這種需求，因為老年人更容易患有神經系統疾病和慢性疼痛。由於這些因素的結合，神經調節設備市場預計在 2024 年至 2030 年的預測期內將出現正成長。

由於神經調節設備在治療中的廣泛應用，神經系統疾病盛行率的上升預計將顯著推動市場。根據世界衛生組織 (WHO) 2024 年 3 月提供的數據，2021 年偏頭痛和其他頭痛疾病影響了全球 31 億人。

根據帕金森氏症基金會2022年發布的數據，美國每年約有9萬人被診斷出患有帕金森氏症（PD），預計到2030年這一數字將達到120萬人。隨著神經系統疾病盛行率持續上升，對神經調節設備的需求預計將增加，進一步推動市場成長。

本報告提供全球神經調節設備市場相關調查，提供市場概要，以及各類型，各產品，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

Medtronic
Abbott Laboratories
Boston Scientific Corporation
LivaNova PLC
NeuroSigma, Inc.
NEVRO CORP.
Synapse Biomedical Inc.
NeuroPace, Inc.
Bioventus
Soterix Medical Inc.
Neuronetics Inc.
ALEVA NEUROTHERAPEUTICS
Magstim
SPR Therapeutics, Inc.
Theranica Bio-Electronics Ltd.
electroCore, Inc.
Neuros Medical
Magnus Medical, Inc.
Integer Holdings Corporation
Mainstay Medical

第9章 KOL的見解

第10章計劃的方法

第11章關於DelveInsight

第12章免責聲明和諮詢方式

簡介目錄圖表

Product Code: DIMDCL0029

Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a static CAGR forecast till 2030 owing to growing prevalence of neurological disorders and rise in numbers of patients suffering from chronic pain.

The neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030 to reach USD 9.56 billion by 2030. The demand for neuromodulation devices is primarily driven by the growing prevalence of neurological disorders and the increasing number of patients suffering from chronic pain. Additionally, increasing research and development activities, along with collaborations among key players, are significantly contributing to market growth. The rising aging population further compounds this demand, as older adults are more susceptible to neurological conditions and chronic pain. These factors collectively position the neuromodulation devices market for positive growth during the forecast period from 2024 to 2030.

Neuromodulation Devices Market Dynamics:

The growing prevalence of neurological disorders is anticipated to significantly propel the market, driven by the widespread application of neuromodulation devices in their treatment. According to data provided by the World Health Organization (WHO) in March 2024, migraine and other headache disorders affected 3.1 billion people globally in 2021.

Data from the Parkinson's Foundation in 2022 indicates that approximately 90,000 individuals are diagnosed with Parkinson's disease (PD) each year in the United States, with projections suggesting that the number of affected individuals will reach 1.2 million by 2030. As the prevalence of neurological conditions continues to rise, the demand for neuromodulation devices is expected to increase, further driving market growth.

Additionally, data from the WHO in June 2023 revealed that around 619 million people were living with lower back pain (LBP) in 2020, with projections indicating that this number is expected to rise to approximately 843 million cases by 2050 worldwide. This increase in LBP cases is primarily attributed to population growth and an aging demographic. Restorative neurostimulation devices are designed to trigger repeated contractions of the multifidus muscles, effectively restoring their strength and stabilizing the spine. As the prevalence of chronic pain continues to rise, the demand for neuromodulation devices is expected to increase, significantly propelling market growth.

Key players in the industry are increasingly focusing on research and development to create innovative neuromodulation systems, further enhancing market growth. For instance, in April 2024, Magnus Medical, Inc., a company specializing in therapeutic neuromodulation, launched the SAINT neuromodulation system specifically designed for treating major depressive disorders. This system utilizes structural and functional magnetic resonance imaging (MRI) scans to guide a proprietary algorithm that accurately identifies the precise anatomical targets for neurostimulation in individuals with major depression. By optimizing treatment effectiveness through targeted stimulation, this innovative approach aims to improve patient outcomes and enhance the overall efficacy of depression therapies. Such advancements are expected to significantly enhance patient outcomes and further drive market growth.

However, certain factors, such as the high cost of these devices and the risk of device-associated complications, may constrain the growth of the neuromodulation devices market.

Neuromodulation Devices Market Segment Analysis:

In the product segment of the neuromodulation devices market, spinal cord stimulators are expected to hold a significant market share during the forecast period. This is attributed to the growing patient population suffering from chronic pain, failed back syndrome, lower back pain, and complex regional pain syndrome (CRPS). According to data from the Centers for Disease Control and Prevention (CDC) in April 2023, it was estimated that 20.9% of adults, accounting for approximately 51.6 million individuals, were suffering from chronic pain. Of these, 6.9%, or about 17.1 million people, experienced high-impact chronic pain in 2021 in the United States, which significantly restricted their daily activities. Spinal cord stimulation devices are effective in treating various types of chronic pain, thereby driving segment growth and contributing to the overall expansion of the neuromodulation devices market.

Recent advancements in spinal cord stimulators, such as rechargeable batteries and wireless remote technology, are also contributing to segment growth. For instance, in December 2022, Abbott Laboratories launched the Eterna(TM) spinal cord stimulation (SCS) system for the treatment of chronic pain. The Eterna SCS system incorporates Abbott's proprietary BurstDR stimulation, which mimics the natural firing patterns found in the brain, providing superior pain relief. This neuromodulation device offers an optimized experience by allowing wireless charging as infrequently as five times per year. Such developments by key players are expected to drive market growth.

Overall, these factors are likely to fuel segment growth and foster the expansion of the neuromodulation devices market during the forecast period.

North America is expected to dominate the overall neuromodulation devices market:

North America is expected to dominate the overall neuromodulation devices market during the forecast period. This dominance can be attributed to the rising number of patients suffering from neurological disorders and increasing product development activities by key players. Additionally, the growing geriatric population is a significant factor contributing to the growth of the neuromodulation devices market in this region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in April 2023, an estimated 6.7 million people aged 65 years or older were living with Alzheimer's disease, with projections indicating this number could nearly triple, reaching 14 million by 2060 in the United States. The rising prevalence of various neurological disorders is likely to be a key driver for the growth of the neuromodulation devices market in North America.

Further supporting this trend, the CDC reported in May 2024 that approximately 3 million people were suffering from epilepsy in the United States in 2021. Such active cases encourage key players to develop neuromodulation devices specifically for epilepsy treatment. For example, in March 2021, NeuroPace, Inc. announced that it received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for its RNS(R) System, which is designed to treat idiopathic generalized epilepsy. The RNS System is a brain-responsive neuromodulation system that delivers personalized, targeted treatment directly at the seizure source and serves as adjunctive therapy for adults suffering from drug-resistant focal epilepsy. These factors are likely to drive significant growth in the neuromodulation devices market in North America.

Moreover, the Asia-Pacific region is poised for future growth in the neuromodulation devices market. This potential is driven by improving healthcare infrastructure, increasing per capita healthcare expenditure, rising disposable income, and a growing elderly population. Additionally, recent product development activities among key manufacturers aiming to expand their product portfolios in the APAC region will also boost the market. For instance, in 2021, Neurolief Ltd., a neurotechnology innovator, entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. to develop and market Relivion(R), a non-invasive brain neuromodulation device for migraine and depression in Japan. This device is designed for placement around the head, delivering targeted stimulation to the occipital and trigeminal nerves. This targeted stimulation generates a cumulative effect by releasing neurotransmitters in the brainstem, modulating brain networks, and ultimately aiding in pain management.

Neuromodulation Devices Market Key Players:

Some of the key market players operating in the neuromodulation devices market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.

Recent Developmental Activities in the Neuromodulation Devices Market:

In January 2024, Boston Scientific Corporation announced that it had entered into a definitive agreement to acquire Axonics, Inc. for an amount of USD 3.4 billion. Through this acquisition, Boston Scientific expanded its neurostimulation device product portfolio with advanced technology development in sacral neuromodulation.
In March 2022, Bioventus announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance to the next-generation StimRouter(R) Neuromodulation System for the treatment of chronic pain. StimRouter is a minimally invasive neuromodulation medical device comprising a thin implanted lead with a conductive electrode, an external electric field conductor (E-EFC), and the StimRouter Plus Mobile Application.
In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.
In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.

Key Takeaways from the Neuromodulation Devices Market Report Study

Market size analysis for current Neuromodulation Devices Market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
Key companies dominating the Neuromodulation Devices market.
Various opportunities available for the other competitors in the Neuromodulation Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current Neuromodulation Devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Neuromodulation Devices market growth in the coming future?

Target Audience who can be benefited from this Neuromodulation Devices Market Report Study

Neuromodulation Devices product providers
Research organizations and consulting companies
Neuromodulation Devices related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in Neuromodulation Devices
Various end-users who want to know more about the Neuromodulation Devices Market and the latest technological developments in the Neuromodulation Devices Market.

Frequently Asked Questions for the Neuromodulation Devices Market:

1. What are Neuromodulation Devices?

Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord, or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.

2. What is the market for Neuromodulation Devices?

The neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030 to reach USD 9.56 billion by 2030.

3. What are the drivers for the Neuromodulation Devices market?

The neuromodulation devices market is slated to witness prosperity owing to factors such as the growing prevalence of neurological disorders and the rise in the number of patients suffering from chronic pain. Increasing R&D activities and collaboration among key players and the rising aging population are the key factors that are responsible for contributing to the positive growth of the neuromodulation devices market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Neuromodulation Devices market?

Some of the key market players operating in the neuromodulation devices market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.

5. Which region has the highest share in the Neuromodulation Devices market?

North America is expected to dominate the overall neuromodulation devices market during the forecast period from 2024 to 2030. This domination is due to the rise in several patients suffering from neurological disorders and increasing product development activities by key players. Additionally, the growing geriatric population is another key factor contributing to the growth of the neuromodulation devices market in this region.

1. Neuromodulation Devices Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Neuromodulation Devices Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Neuromodulation Devices Market Key Factors Analysis

5.1. Neuromodulation Devices Market Drivers
- 5.1.1. The growing prevalence of neurological disorder
- 5.1.2. Rise in the number of patients suffering from chronic pain
- 5.1.3. Increasing R&D activities and collaboration among key players
- 5.1.4. Rising aging population
5.2. Neuromodulation Devices Market Restraints and Challenges
- 5.2.1. Risks of device-associated complications
- 5.2.2. High cost of neurostimulation devices
5.3. Neuromodulation Devices Market Opportunity
- 5.3.1. The integration of artificial intelligence in neuromodulation devices
- 5.3.2. Emergence of digital health to enhance personalized treatment

6. Neuromodulation Devices Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Neuromodulation Devices Market Assessment

7.1. By Type
- 7.1.1. Invasive
- 7.1.2. Non-Invasive
7.2. By Product
- 7.2.1. Spinal Cord Stimulators
- 7.2.2. Vagus Nerve Stimulators
- 7.2.3. Deep Brain Stimulators
- 7.2.4. Sacral Nerve Stimulators
- 7.2.5. Transcranial Magnetic Stimulators
- 7.2.6. Others
7.3. By Application
- 7.3.1. Pain Management
- 7.3.2. Neurological Disorder
- 7.3.3. Respiratory Disorders
- 7.3.4. Others
7.4. By End-User
- 7.4.1. Hospitals
- 7.4.2. Specialty Clinics
- 7.4.3. Others
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.1.2. Canada Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.1.3. Mexico Neuromodulation Devices Market Size in USD million (2021-2030)
- 7.5.2. Europe
  - 7.5.2.1. France Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.2.2. Germany Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.2.3. United Kingdom Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.2.4. Italy Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.2.5. Spain Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.2.6. Rest of Europe Neuromodulation Devices Market Size in USD million (2021-2030)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.3.2. Japan Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.3.3. India Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.3.4. Australia Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.3.5. South Korea Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.3.6. Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.4.2. Africa Neuromodulation Devices Market Size in USD million (2021-2030)
  - 7.5.4.3. South America Neuromodulation Devices Market Size In USD Million (2021-2030)

8. Neuromodulation Devices Market Company and Product Profiles

8.1. Medtronic
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Abbott Laboratories
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Boston Scientific Corporation
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. LivaNova PLC
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. NeuroSigma, Inc.
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. NEVRO CORP.
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Synapse Biomedical Inc.
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. NeuroPace, Inc.
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Bioventus
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. Soterix Medical Inc.
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Neuronetics Inc.
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. ALEVA NEUROTHERAPEUTICS
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. Magstim
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. SPR Therapeutics, Inc.
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Theranica Bio-Electronics Ltd.
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. electroCore, Inc.
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Neuros Medical
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. Magnus Medical, Inc.
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Integer Holdings Corporation
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. Mainstay Medical
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy